IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Login to save this paper or follow this series

Tarif forfaitaire de responsabilité : quels impacts sur le pharmacien ?

  • Carine Franc

    (CERMES3 - Centre de recherche, médecine, sciences, santé, santé mentale, société - CNRS : UMR8211 - Université Paris V - Paris Descartes - INSERM : U988 - Ecole des Hautes Etudes en Sciences Sociales (EHESS))

  • Laurent Granier

    (GATE Lyon Saint-Etienne - Groupe d'analyse et de théorie économique - CNRS : UMR5824 - Université Lumière - Lyon II - École Normale Supérieure - Lyon)

  • Sébastien Trinquard

    (UNOCAM - Union nationale des organismes d'assurance maladie complémentaire - UNOCAM)

L'objectif de cet article est d'étudier l'impact du tarif forfaitaire de responsabilité (TFR) sur la part de la marge du grossiste attribuée au pharmacien et sur l'effort de substitution entre marque et générique. Nous considérons une situation dans laquelle le génériqueur vend directement son générique au pharmacien et le laboratoire de marque vend son princeps par l'intermédiaire d'un grossiste. Nous supposons que les produits sont verticalement différenciés et nous résolvons un jeu en deux étapes. A la première étape, le génériqueur détermine la part de la marge du grossiste qu'il consent au pharmacien afin de l'inciter à substituer et, si un tarif forfaitaire de responsabilité est introduit, les firmes se concurrencent en prix. A la seconde étape, le pharmacien choisit son effort de substitution. Nous montrons que l'introduction du TFR augmente la part de la marge du grossiste allouée au pharmacien par le génériqueur, mais diminue l'effort de substitution du pharmacien.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://halshs.archives-ouvertes.fr/docs/00/80/04/57/PDF/1309.pdf
Download Restriction: no

Paper provided by HAL in its series Working Papers with number halshs-00800457.

as
in new window

Length:
Date of creation: 13 Mar 2013
Date of revision:
Handle: RePEc:hal:wpaper:halshs-00800457
Note: View the original document on HAL open archive server: http://halshs.archives-ouvertes.fr/halshs-00800457
Contact details of provider: Web page: http://hal.archives-ouvertes.fr/

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

as in new window
  1. Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås, 2007. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," CESifo Working Paper Series 2059, CESifo Group Munich.
  2. Huttin, Christine, 1996. "A critical review of the remuneration systems for pharmacists," Health Policy, Elsevier, vol. 36(1), pages 53-68, April.
  3. Dalen, Dag Morten & Strøm, Steinar & Haabeth, Tonje, 2005. "Price regulation and generic competition in the pharmaceutical market," Memorandum 33/2005, Oslo University, Department of Economics.
  4. Sara Ellison Fisher & Iain Cockburn & Zvi Griliches & Jerry Hausman, 1997. "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins," RAND Journal of Economics, The RAND Corporation, vol. 28(3), pages 426-446, Autumn.
  5. Nina Pavcnik, 2002. "Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?," RAND Journal of Economics, The RAND Corporation, vol. 33(3), pages 469-487, Autumn.
  6. Lundin, Douglas, 2000. "Moral hazard in physician prescription behavior," Journal of Health Economics, Elsevier, vol. 19(5), pages 639-662, September.
  7. Susana Narciso, 2005. "Retailing Policies for Generic Medicines," International Journal of Health Care Finance and Economics, Springer, vol. 5(2), pages 165-190, June.
  8. Konigbauer, Ingrid, 2007. "Advertising and generic market entry," Journal of Health Economics, Elsevier, vol. 26(2), pages 286-305, March.
  9. Brekke, Kurt R. & Konigbauer, Ingrid & Straume, Odd Rune, 2007. "Reference pricing of pharmaceuticals," Journal of Health Economics, Elsevier, vol. 26(3), pages 613-642, May.
  10. Mats A. Bergman & Niklas Rudholm, 2003. "The Relative Importance of Actual and Potential Competition: Empirical Evidence From the Pharmaceuticals Market," Journal of Industrial Economics, Wiley Blackwell, vol. 51(4), pages 455-467, December.
  11. Zweifel, Peter & Crivelli, Luca, 1996. "Price Regulation of Drugs: Lessons from Germany," Journal of Regulatory Economics, Springer, vol. 10(3), pages 257-73, November.
Full references (including those not matched with items on IDEAS)

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:hal:wpaper:halshs-00800457. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (CCSD)

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.